Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07269470

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Conditions: Chronic Myeloid Leukemia

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 40

Sponsor: M.D. Anderson Cancer Center

Location: The University of Texas M. D. Anderson Cancer Center Houston Texas

Summary

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Eligibility Criteria

Inclusion Criteria: Adult patients age ≥18 years. Patients must have a diagnosis of Ph-positive or BCR::ABL1 positive CML in chronic phase. Patients who received prior hydroxyurea, 1 to 2 doses of cytarabine, and/or an FDA approved TKI for \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07269470). StuddyBuddy aggregates publicly available trial information.